Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features

Leukemia

Volumn 20, Issue 9, 2006, Pages 1641-1644

  Wang, S A ^a   Hasserjian, R P ^b   Loew, J M ^c   Sechman, E V ^a   Jones, D ^d   Hao, S ^a   Liu, Q ^a   Zhao, W ^d   Mehdi, M ^a   Galili, N ^a   Woda, B ^a   Raza, A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; AGE DISTRIBUTION; AGED; BONE MARROW BIOPSY; CANCER SURVIVAL; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPING; LETTER; MAJOR CLINICAL STUDY; MALE; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MONOSOMY; MONOSOMY 5; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SCORING SYSTEM; SEQUENCE ANALYSIS; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTOSIS;

EID: 33747610392     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404316     Document Type: Letter

References (8)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 484: 1144-1148.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell 2005; 7: 387-397.
3. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferaive disorders and myelodysplastic syndromes. Blood 2005; 106: 1207-1209.
4. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370-3373.
5. Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359-2360.
6. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17 - 1992. Repeated bouts of hematochezia in an 80-year-old hypertensive man. N Engl J Med 1992; 326: 1137-1146.
7. Shaw GR. Ringed sideroblasts with thrombocytosis: An uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005; 131: 180-184.
8. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM. Essential thrombocythemia with ringed sideroblasts: A heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002; 87: 392-399.